Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

It's No Cosentyx/Taltz But Ilumya Pleases Customers, Says Sun

Executive Summary

Sun Pharma acknowledged the intense competition that awaits its psoriasis asset, Ilumya (tildrakizumab) in the US, but maintained that the overall profile of the IL-23p19 inhibitor, which is expected to debut in Q2FY19, was “liked” by customers.

You may also be interested in...



Sun’s Ilumya Gnaws At US Psoriasis Market

Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.

Tildrakizumab Set For Europe Debut - Can It Make A Dent?

Almirall's Ilumetri, licensed from Sun Pharma, has been cleared by the European Commission, upping the competition quotient in the psoriasis market and pitting the product directly against Johnson & Johnson's Tremfya.

Sun Hopes Cequa’s Nano Formulation Makes Big Impact

Sun’s now-approved higher concentration, quicker-acting formulation of cyclosporine A could offer competitive advantage in dry eye versus Allergan’s Restasis, but is it enough to offset lower costs of pending generic cyclosporines?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123695

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel